{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+of+aGVHD&page=4",
    "query": {
      "condition": "Prevention of aGVHD",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 356,
    "total_pages": 36,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+of+aGVHD&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+of+aGVHD&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T10:23:27.165Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04908683",
      "title": "A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Viruses",
        "Lower Respiratory Tract Disease"
      ],
      "interventions": [
        {
          "name": "Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 25236,
      "start_date": "2021-07-21",
      "completion_date": "2023-07-21",
      "has_results": true,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 156,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04908683"
    },
    {
      "nct_id": "NCT04444895",
      "title": "A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Angioedema"
      ],
      "interventions": [
        {
          "name": "Lanadelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2021-02-05",
      "completion_date": "2023-05-05",
      "has_results": true,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04444895"
    },
    {
      "nct_id": "NCT02528877",
      "title": "Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia in Remission",
        "Primary Myelofibrosis",
        "Primary Myelofibrosis, Prefibrotic Stage",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Ruxolitinib Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-09-14",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02528877"
    },
    {
      "nct_id": "NCT03320642",
      "title": "GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Calcineurin inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2018-02-27",
      "completion_date": "2022-02-17",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Maywood, Illinois + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03320642"
    },
    {
      "nct_id": "NCT02641561",
      "title": "Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Post-ERCP Acute Pancreatitis"
      ],
      "interventions": [
        {
          "name": "Indomethacin",
          "type": "DRUG"
        },
        {
          "name": "Lactated Ringer's Solution",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cooper Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2014-10",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 1,
      "location_summary": "Camden, New Jersey",
      "locations": [
        {
          "city": "Camden",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02641561"
    },
    {
      "nct_id": "NCT00343460",
      "title": "APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nausea and Vomiting",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "APF530",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Palonosetron Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Heron Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 1428,
      "start_date": "2006-06",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 52,
      "location_summary": "Anniston, Alabama • Glendale, Arizona • Tucson, Arizona + 46 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343460"
    },
    {
      "nct_id": "NCT00227370",
      "title": "Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cytomegalovirus Infections"
      ],
      "interventions": [
        {
          "name": "valganciclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 136,
      "start_date": "2003-07",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2024-10-04",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00227370"
    },
    {
      "nct_id": "NCT00228254",
      "title": "Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pneumonia",
        "Diarrhea",
        "Acute Upper Respiratory Tract Infections"
      ],
      "interventions": [
        {
          "name": "Zinc (12.5 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "vitamin A 10,000 IU per week",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tufts University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "36 Months",
        "sex": "ALL",
        "summary": "6 Months to 36 Months"
      },
      "enrollment_count": 2582,
      "start_date": "2000-01",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2005-09-28",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00228254"
    },
    {
      "nct_id": "NCT02663622",
      "title": "Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Hematopoietic Stem Cell Transplantation",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Efprezimod alfa",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2016-09-19",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02663622"
    },
    {
      "nct_id": "NCT00382109",
      "title": "Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "B-cell Childhood Acute Lymphoblastic Leukemia",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Graft Versus Host Disease",
        "L1 Childhood Acute Lymphoblastic Leukemia",
        "L2 Childhood Acute Lymphoblastic Leukemia",
        "T-cell Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "sirolimus",
          "type": "DRUG"
        },
        {
          "name": "total body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 146,
      "start_date": "2007-03",
      "completion_date": "2017-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-08-07",
      "last_synced_at": "2026-10-07T10:23:27.165Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Duarte, California • Oakland, California + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00382109"
    }
  ]
}